Tnbc clinical trials

Explore recruiting tnbc clinical trials.

Recruiting tnbc studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Tnbc trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Biomarker discovery randomized phase IIb trial with carboplatin-cyclophosphamide versus paclitaxel with or without atezolizumab as first-line treatment in advanced triple negative breast cancer

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Sac-TMT (Sacituzumab Tirumotecan, MK-2870) Followed by Carboplatin/Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC) or Hormone Receptor-low positive/HER2-negative Breast Cancer

France, Sweden, Poland, Spain, Finland, Portugal +8 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Immune induction strategies to improve response to immune checkpoint blockade in triple negative breast cancer (TNBC) patients: the TONIC-2 trial

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

A randomised phase II trial evaluating the efficacy of a nivolumab monotherapy lead in “window” or commencement of nivolumab concurrently with paclitaxel and carboplatin as neoadjuvant therapy in early stage triple negative breast cancers

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase II, Multicenter, Randomized, Double-Blind Study of Tobemstomig/RO7247669 Combined with Nab-Paclitaxel Compared with Pembrolizumab Combined with Nab-Paclitaxel in Participants with Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

Czechia, Hungary, Poland, Spain, Germany, Denmark +2 more

Therapeutic exploratory (Phase II) EU CTIS Study details

NOvel Immunotherapy strategies for advanced Triple negative breast Cancer (TNBC) patients: TONIC-3 trial

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

Tnbc trials by city

Tnbc in Toronto Tnbc in Vancouver Tnbc in Montreal Tnbc in Calgary Tnbc in Edmonton Tnbc in Ottawa Tnbc in Winnipeg Tnbc in Quebec City Tnbc in Hamilton Tnbc in Kitchener Tnbc in London Tnbc in Halifax Tnbc in New York Tnbc in Los Angeles Tnbc in Chicago Tnbc in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease